Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| iBio, Inc.IBIO · Entity 6906 | Chief Financial Officer | September 05, 2014 | April 05, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
iBio, Inc.
Report date September 05, 2014 · Filed April 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.49 · Expires 2024-09-05 | Direct | 150,000 |
Reported balance
After 2014-09-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2014-09-05 · Grant · Acquired 50,000 · Balance 150,000 F1: (1) Vesting starts 7/1/2014, in equal annual installments over three years. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2025-09-04 | Direct | 300,000 |
Reported balance
After 2015-09-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2015-09-04 · Grant · Acquired 150,000 · Balance 300,000 F2: (2) Vesting starts 7/1/2015, in equal annual installments over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: (1) Vesting starts 7/1/2014, in equal annual installments over three years.
F2: (2) Vesting starts 7/1/2015, in equal annual installments over three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2015 Filed Apr 5, 2017 20:50 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 150,000 | $1.72 Strike: $1.72 | $258,000.00 |
DisclosureSEC source: 0001638599-17-000350 · doc4_4654.xml · derivative · entry 2 GIANNONE MARK A · CIK 0001597154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 150,000 shares Expires 2025-09-04 F2 · derivative.exercise_date: (2) Vesting starts 7/1/2015, in equal annual installments over three years. Read SEC document |
| September 05, 2014 Filed Apr 5, 2017 20:50 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.49 Strike: $0.49 | $24,500.00 |
DisclosureSEC source: 0001638599-17-000350 · doc4_4654.xml · derivative · entry 1 GIANNONE MARK A · CIK 0001597154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 50,000 shares Expires 2024-09-05 F1 · derivative.exercise_date: (1) Vesting starts 7/1/2014, in equal annual installments over three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.